mGlu5 negative allosteric modulators: a patent review (2013 - 2016)
{{output}}
The pursuit of small molecule mGlu5 NAMs as treatments for a variety of psychiatric and neurodegenerative disorders has developed into a mature field. In addition to extensive preclinical studies, multiple compounds have advanced into clinical trials with the ... ...